Literature DB >> 23211515

Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling.

Charles Harris1, Donald J Roohk, Mark Fitch, Benjamin M Boudignon, Bernard P Halloran, Marc K Hellerstein.   

Abstract

Glucocorticoids are extremely effective anti-inflammatory therapies, but their clinical use is limited due to severe side effects, including osteoporosis, muscle wasting, fat redistribution, and skin thinning. Here we use heavy water labeling and mass spectrometry to measure fluxes through metabolic pathways impacted by glucocorticoids. We combine these methods with measurements of body composition in corticotropin-releasing hormone (CRH)-transgenic (Tg)(+) mice that have chronically elevated, endogenously produced corticosterone and a phenotype that closely mimics Cushing's disease in humans. CRH-Tg(+) mice had increased adipose mass, adipose triglyceride synthesis, and greatly increased triglyceride/fatty acid cycling in subcutaneous and abdominal fat depots and increased de novo lipogenesis in the abdominal depot. In bone, CRH-Tg(+) mice had decreased bone mass, absolute collagen synthesis rates, and collagen breakdown rate. In skin, CRH-Tg(+) mice had decreased skin thickness and absolute collagen synthesis rates but no decrease in the collagen breakdown rate. In muscle, CRH-Tg(+) mice had decreased muscle mass and absolute protein synthesis but no decrease in the protein breakdown rate. We conclude that chronic exposure to endogenous glucocorticoid excess in mice is associated with ongoing decreases in bone collagen, skin collagen, and muscle protein synthesis without compensatory reduction (coupling) of breakdown rates in skin and muscle. Both of these actions contribute to reduced protein pool sizes. We also conclude that increased cycling between triglycerides and free fatty acids occurs in both abdominal and subcutaneous fat depots in CRH-Tg(+) mice. CRH-Tg mice have both increased lipolysis and increased triglyceride synthesis in adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23211515      PMCID: PMC3566431          DOI: 10.1152/ajpendo.00154.2012

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  42 in total

1.  Cortisol--cause and cure for metabolic syndrome?

Authors:  B R Walker
Journal:  Diabet Med       Date:  2006-12       Impact factor: 4.359

2.  Measurement of protein turnover rates by heavy water labeling of nonessential amino acids.

Authors:  Robert Busch; Yoo-Kyeong Kim; Richard A Neese; Valerie Schade-Serin; Michelle Collins; Mohamad Awada; James L Gardner; Carine Beysen; Michael E Marino; Lisa M Misell; Marc K Hellerstein
Journal:  Biochim Biophys Acta       Date:  2006-01-24

3.  Recovery of human skin collagen synthesis after short-term topical corticosteroid treatment and comparison between young and old subjects.

Authors:  K M Haapasaari; J Risteli; A Oikarinen
Journal:  Br J Dermatol       Date:  1996-07       Impact factor: 9.302

Review 4.  CRH overproduction in transgenic mice: behavioral and immune system modulation.

Authors:  M P Stenzel-Poore; J E Duncan; M B Rittenberg; A C Bakke; S C Heinrichs
Journal:  Ann N Y Acad Sci       Date:  1996-03-22       Impact factor: 5.691

5.  Dietary dried plum increases bone mass in adult and aged male mice.

Authors:  Bernard P Halloran; Thomas J Wronski; Douglas C VonHerzen; Vivian Chu; Xuechun Xia; Jennifer E Pingel; Alyssa A Williams; Brenda J Smith
Journal:  J Nutr       Date:  2010-08-25       Impact factor: 4.798

6.  Physiologic and pharmacologic factors influencing glyceroneogenic contribution to triacylglyceride glycerol measured by mass isotopomer distribution analysis.

Authors:  Jerry L Chen; Erin Peacock; Waheeda Samady; Scott M Turner; Richard A Neese; Marc K Hellerstein; Elizabeth J Murphy
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

7.  Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA.

Authors:  R A Neese; L M Misell; S Turner; A Chu; J Kim; D Cesar; R Hoh; F Antelo; A Strawford; J M McCune; M Christiansen; M K Hellerstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-07       Impact factor: 11.205

8.  Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect.

Authors:  P Autio; A Oikarinen; J Melkko; J Risteli; L Risteli
Journal:  Br J Dermatol       Date:  1994-11       Impact factor: 9.302

9.  Time course of the effect of catabolic doses of corticosterone on protein turnover in rat skeletal muscle and liver.

Authors:  B R Odedra; P C Bates; D J Millward
Journal:  Biochem J       Date:  1983-08-15       Impact factor: 3.857

10.  Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis.

Authors:  Chi-Yi Yu; Oleg Mayba; Joyce V Lee; Joanna Tran; Charlie Harris; Terence P Speed; Jen-Chywan Wang
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

View more
  13 in total

Review 1.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 2.  Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues.

Authors:  Rucha Patel; Jasmine Williams-Dautovich; Carolyn L Cummins
Journal:  Mol Endocrinol       Date:  2014-04-25

3.  Transcriptional regulation of FoxO3 gene by glucocorticoids in murine myotubes.

Authors:  Taiyi Kuo; Patty H Liu; Tzu-Chieh Chen; Rebecca A Lee; Jenny New; Danyun Zhang; Cassandra Lei; Andy Chau; Yicheng Tang; Edna Cheung; Jen-Chywan Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-12       Impact factor: 4.310

Review 4.  Polymorphisms and mutations in the melanocortin-3 receptor and their relation to human obesity.

Authors:  Andrew P Demidowich; Joo Yun Jun; Jack A Yanovski
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

5.  The glucocorticoid-Angptl4-ceramide axis induces insulin resistance through PP2A and PKCζ.

Authors:  Tzu-Chieh Chen; Daniel I Benjamin; Taiyi Kuo; Rebecca A Lee; Mei-Lan Li; Darryl J Mar; Damian E Costello; Daniel K Nomura; Jen-Chywan Wang
Journal:  Sci Signal       Date:  2017-07-25       Impact factor: 8.192

6.  Flattening of circadian glucocorticoid oscillations drives acute hyperinsulinemia and adipocyte hypertrophy.

Authors:  Stefan Tholen; Roma Patel; Agnieszka Agas; Kyle M Kovary; Atefeh Rabiee; Hayley T Nicholls; Ewa Bielczyk-Maczyńska; Wenting Yang; Fredric B Kraemer; Mary N Teruel
Journal:  Cell Rep       Date:  2022-06-28       Impact factor: 9.995

Review 7.  Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity.

Authors:  Mi-Jeong Lee; Pornpoj Pramyothin; Kalypso Karastergiou; Susan K Fried
Journal:  Biochim Biophys Acta       Date:  2013-06-02

8.  Glucocorticoid Receptor Signaling Is Not Required for In Vivo Adipogenesis.

Authors:  Kevin T Bauerle; Irina Hutson; Erica L Scheller; Charles A Harris
Journal:  Endocrinology       Date:  2018-05-01       Impact factor: 4.736

9.  Gene expression changes in subcutaneous adipose tissue due to Cushing's disease.

Authors:  Irit Hochberg; Innocence Harvey; Quynh T Tran; Erin J Stephenson; Ariel L Barkan; Alan R Saltiel; William F Chandler; Dave Bridges
Journal:  J Mol Endocrinol       Date:  2015-07-06       Impact factor: 5.098

10.  An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess.

Authors:  Liz Bentley; Christopher T Esapa; M Andrew Nesbit; Rosie A Head; Holly Evans; Darren Lath; Cheryl L Scudamore; Tertius A Hough; Christine Podrini; Fadil M Hannan; William D Fraser; Peter I Croucher; Matthew A Brown; Steve D M Brown; Roger D Cox; Rajesh V Thakker
Journal:  Endocrinology       Date:  2013-12-03       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.